CDXS Codexis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDXS

Price (delayed)

$1.67

Market cap

$182.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.33

Enterprise value

$226.26M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 39

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve ...

Highlights
The EPS has surged by 59% year-on-year and by 8% since the previous quarter
The company's net income has surged by 53% YoY and by 4% QoQ
Codexis's gross profit has surged by 52% YoY but it has decreased by 2.6% QoQ
CDXS's gross margin is up by 12% year-on-year but it is down by 2.1% since the previous quarter
CDXS's quick ratio is down by 50% year-on-year and by 46% since the previous quarter
The equity has declined by 41% year-on-year and by 24% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.codexis.com
Peers: BCPC MRK PFE DD

Key stats

What are the main financial stats of CDXS

CDXS stock price

How has the Codexis stock price performed over time
Intraday
5.7%
1 week
7.05%
1 month
-24.09%
1 year
-40.78%
YTD
2.45%
QTD
-26.11%

Financial performance

How have Codexis's revenue and profit performed over time
Revenue
$77.68M
Gross profit
$67.6M
Operating income
-$27.66M
Net income
-$30.72M
Gross margin
87%
Net margin
-39.6%
The net margin has soared by 65% YoY and by 3.4% from the previous quarter
The operating margin has surged by 64% year-on-year and by 5% since the previous quarter
The company's net income has surged by 53% YoY and by 4% QoQ
The company's operating income has surged by 52% YoY and by 6% QoQ

Price vs fundamentals

How does CDXS's price correlate with its fundamentals

Growth

What is Codexis's growth rate over time

Valuation

What is Codexis stock price valuation
P/E
N/A
P/B
4.61
P/S
1.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
The EPS has surged by 59% year-on-year and by 8% since the previous quarter
The equity has declined by 41% year-on-year and by 24% since the previous quarter
CDXS's price to book (P/B) is 4.8% higher than its 5-year quarterly average of 4.4
The price to sales (P/S) is 61% lower than the 5-year quarterly average of 5.0 and 27% lower than the last 4 quarters average of 2.7
CDXS's revenue is up by 36% year-on-year

Efficiency

How efficient is Codexis business performance
The return on sales has surged by 66% year-on-year and by 6% since the previous quarter
The company's return on invested capital has surged by 52% YoY and by 2.2% QoQ
Codexis's return on assets has increased by 49% YoY
Codexis's return on equity has increased by 30% YoY but it has decreased by 9% QoQ

Dividends

What is CDXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXS.

Financial health

How did Codexis financials performed over time
CDXS's total assets is 38% greater than its total liabilities
CDXS's quick ratio is down by 50% year-on-year and by 46% since the previous quarter
Codexis's current ratio has decreased by 47% YoY and by 43% QoQ
The debt is 120% more than the equity
The company's debt to equity has surged by 77% YoY and by 30% QoQ
The equity has declined by 41% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.